The future of immunoglobulin therapy: An overview of the 2nd international workshop on natural antibodies in health and disease

Miescher, Sylvia; Käsermann, Fabian

doi:10.1016/j.autrev.2013.01.003

Cited by 14 publications

(7 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IVIG is becoming increasingly common as a treatment for autoimmune and systemic inflammatory diseases, based on its immunomodulatory and anti‐inflammatory potential . IVIG can protect against some autoimmune diseases by increasing the number of peripheral T reg cells, but the mechanism of IVIG treatment is unknown .…”

Section: Discussionmentioning

confidence: 99%

Regulatory T cell microRNA expression changes in children with acute Kawasaki disease

et al. 2014

Clinical and Experimental Immunology

View full text Add to dashboard Cite

glucocorticoid-induced tumour necrosis factor-receptor (GITR), cytotoxic T lymphocyte antigen (CTLA)-4)] were significantly lower in KD patients (P < 0·05). MiR-155 and miR-21 levelswere significantly down-regulated and miR-31 expression was higher in KD patients (P < 0·05). Plasma interleukin (IL)-6 concentrations, pSTAT-3 protein levels and suppressors of cytokine signalling (SOCS)-1 mRNA expression were remarkably elevated in acute KD (P < 0·05), while pSTAT-5 protein levels were remarkably decreased in acute KD (P < 0·05). These findings were reversed after intravenous immunoglobulin treatment (P < 0·05). Our results demonstrate that FoxP3 mRNA levels were primarily affected by the miR-155/SOCS1 and the miR-31 signalling pathways. These results suggest that the decrease in FoxP3 + Treg might be associated with decreased expression of miR-155, leading to aberrant SOCS1/STAT-5 signalling and overexpression of miR-31 in patients with acute KD.

show abstract

Section: Discussionmentioning

confidence: 99%

Regulatory T cell microRNA expression changes in children with acute Kawasaki disease

et al. 2014

Clinical and Experimental Immunology

View full text Add to dashboard Cite

show abstract

“…IVIG was originally prescribed for the treatment of primary immunodeficiency and secondary immunodeficiency syndromes where it replenishes levels of serum Ig and provides life-saving protection from infection (reviewed in Refs. [3][4][5]. Although primary immunodeficiency represents a significant proportion of IVIG usage, the larger market share for IVIG is used for the treatment of patients with various chronic and acute autoimmune and inflammatory diseases (6).…”

mentioning

confidence: 99%

Therapeutic Effect of IVIG on Inflammatory Arthritis in Mice Is Dependent on the Fc Portion and Independent of Sialylation or Basophils

Campbell

Miescher

Branch

et al. 2014

The Journal of Immunology

Self Cite

118

103

View full text Add to dashboard Cite

High-dose i.v. Ig (IVIG) is used to treat various autoimmune and inflammatory diseases; however, the mechanism of action remains unclear. Based on the K/BxN serum transfer arthritis model in mice, IVIG suppression of inflammation has been attributed to a mechanism involving basophils and the binding of highly sialylated IgG Fc to DC-SIGN–expressing myeloid cells. The requirement for sialylation was examined in the collagen Ab-induced arthritis (CAbIA) and K/BxN serum transfer arthritis models in mice. High-dose IVIG (1–2 g/kg body weight) suppressed inflammatory arthritis when given prophylactically. The same doses were also effective in the CAbIA model when given subsequent to disease induction. In this therapeutic CAbIA model, the anti-inflammatory effect of IVIG was dependent on IgG Fc but not F(ab′)2 fragments. Removal of sialic acid residues by neuraminidase had no impact on the anti-inflammatory activity of IVIG or Fc fragments. Treatment of mice with basophil-depleting mAbs did not abrogate the suppression of either CAbIA or K/BxN arthritis by IVIG. Our data confirm the therapeutic benefit of IVIG and IgG Fc in Ab-induced arthritis but fail to support the significance of sialylation and basophil involvement in the mechanism of action of IVIG therapy.

show abstract

“…In recent years the use of SCIg in immune-mediated disorders has been the object of increasing interest, mainly in demyelinating neuropathy and inflammatory myopathies, with clinical benefit [18][19][20][21]. Considering all the different pathophysiological mechanisms and the various modalities of action of immunoglobulin, it is not surprising that IVIg can positively influence the outcome of several immunemediated diseases [22][23][24].…”

Section: Rationale For the Use Of Subcutaneous Immunoglobulin (Scig) mentioning

confidence: 98%

Subcutaneous IgG in immune-mediate diseases: proposed mechanisms of action and literature review

Danieli

Gelardi

Pedini

et al. 2014

Autoimmunity Reviews

View full text Add to dashboard Cite

The future of immunoglobulin therapy: An overview of the 2nd international workshop on natural antibodies in health and disease

Cited by 14 publications

References 40 publications

Regulatory T cell microRNA expression changes in children with acute Kawasaki disease

Regulatory T cell microRNA expression changes in children with acute Kawasaki disease

Therapeutic Effect of IVIG on Inflammatory Arthritis in Mice Is Dependent on the Fc Portion and Independent of Sialylation or Basophils

Subcutaneous IgG in immune-mediate diseases: proposed mechanisms of action and literature review

Contact Info

Product

Resources

About